Despite years of experience of returning genetic test results, clinicians and researchers are still faced with many questions, such as what to do about VUS and secondary findings.
A meta-analysis based on genotyping data for more than 400,000 people with or without the disease led to 17 new risk loci mined for candidate genes
Publishing house Hearst is pushing into precision medicine with a $75 million investment in M2Gen, the informatics subsidiary of Moffitt Cancer Center.
In an increasingly diverse field of sequencing assays, Genentech researchers believe they have achieved notable sensitivity, with high multiplexing capability and relatively low cost.
The company's PD-L1 IHC 28-8 pharmDx diagnostic can now be used in cases of urothelial carcinoma and squamous cell carcinoma of the head and neck.
The PHG Foundation's report calls for raising clinician awareness about ctDNA testing technology in order to improve patient access to targeted therapies.
The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments.
The center is developing a method to generate synthetic polymers using reengineered E. coli cells.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.
This white paper describes a benchmarking study of 30 whole-exome sequencing cases in which Diploid's Moon software outperformed another variant interpretation algorithm in ranking causal variants.